Cart
sales@molnova.com
MitoBloCK-6
CAS No. 303215-67-0
MitoBloCK-6( —— )
Catalog No. M35338 CAS No. 303215-67-0
MitoBloCK-6 is a potent Erv1/ALR inhibitor with IC50 values of 900 nM and 700 nM, respectively, and also inhibits Erv2 with an IC50 of 1.4 μM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 31 | Get Quote |
|
| 10MG | 45 | Get Quote |
|
| 25MG | 70 | Get Quote |
|
| 50MG | 116 | Get Quote |
|
| 100MG | 177 | Get Quote |
|
| 200MG | 267 | Get Quote |
|
| 500MG | 464 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameMitoBloCK-6
-
NoteResearch use only, not for human use.
-
Brief DescriptionMitoBloCK-6 is a potent Erv1/ALR inhibitor with IC50 values of 900 nM and 700 nM, respectively, and also inhibits Erv2 with an IC50 of 1.4 μM.
-
DescriptionMitoBloCK-6 is a potent Erv1/ALR inhibitor, with an IC50 of 900 nM and 700 nM, respectively. MitoBloCK-6 also inhibits Erv2 (IC50=1.4 μM). MitoBloCK-6 can induce apoptosis via cytochrome c release in hESCs.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number303215-67-0
-
Formula Weight357.23
-
Molecular FormulaC19H14Cl2N2O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (139.97 mM)
-
SMILESOc1c(Cl)cc(Cl)cc1\C=N\c1ccc(Nc2ccccc2)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Dabir DV, et, al. A small molecule inhibitor of redox-regulated protein translocation into mitochondria. Dev Cell. 2013 Apr 15;25(1):81-92. ?
molnova catalog
related products
-
HNPMI
HNPMI is an EGFR inhibitor that induces G0/G1 phase arrest of CRC cells in colorectal cancer, regulates enzymes associated with apoptosis, and can promote apoptosis, and can be used for the study of colorectal cancer.
-
Nebularine
Nebularine (9-(beta-D-Ribofuranosyl)-9H-purine) is a purine nucleoside analog with a broad spectrum of antitumor activity, targeting inert lymphoid malignancies and inducing apoptosis.
-
Tafasitamab
Tafasitamab (XmAb5574) is an FC-modified humanized monoclonal antibody targeting the human B-cell surface antigen CD19 for the study of diffuse large B-cell lymphoma.
